ASH 2023 | Enhancing clinical care in LR-MDS: managing symptomatic/transfusion-dependent anemia
Rory Shallis, MD, Yale Cancer Center, New Haven, CT, discusses strategies to enhance care for patients with lower-risk myelodysplastic syndromes (LR-MDS). The primary challenge in these patients is the management of symptomatic or transfusion-dependent anemia with red blood cell (RBC) transfusions, erythropoietin stimulating agents (ESAs), or, more recently, erythroid maturation agents (EMAs) such as luspatercept. For those patients who fail on ESAs, novel therapeutic options, such as imetelstat, may provide an alternative treatment option in the future. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Bristol Myers Squibb, Curio Science, Servier, Rigel, Gilead Sciences
